- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA OKs First Drug-Eluting Stents for Use in MI
Two drug-eluting stents from Boston Scientific have become the first to be approved by the FDA for treating patients with acute myocardial infarction (AMI), the company announced.
The paclitaxel-eluting Ion and Taxus Liberté stents gained approval for AMI primarily on the strength of the evidence from the HORIZONS-AMI trial.
HORIZONS-AMI randomized 3,006 patients to bare-metal or Taxus stents. At three years, there were no significant differences in safety, including all-cause death, reinfarction, stent thrombosis, or stroke.
Read the full story: http://hcp.lv/yWMJQg
Source: MedPage Today
Nomogram Predicts Overall Survival in Patients With Ovarian Cancer, Liver Metastases
January 9th 2025Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian cancer and liver metastases (OCLM), outperforming an external model in stability and accuracy.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
